The novel cannabinoid antagonist SM-11 reduces hedonic aspect of food intake through a dopamine-dependent mechanism
Pharmacological Research. 2016-11-01; 113: 108-115
DOI: 10.1016/j.phrs.2016.08.012
Lire sur PubMed
Fois GR(1), Fattore L(2), Murineddu G(3), Salis A(3), Pintore G(3), Asproni B(3), Pinna GA(3), Diana M(4).
Author information:
(1)’G. Minardi’ Cognitive Neuroscience Laboratory, Department of Chemistry and Pharmacy, University of Sassari, Italy. Electronic address:
.
(2)CNR Institute of Neuroscience-Cagliari, National Research Council-Italy, Dept. Biomedical Science, University of Cagliari, Italy.
(3)Department of Chemistry and Pharmacy, University of Sassari, Italy.
(4)’G. Minardi’ Cognitive Neuroscience Laboratory, Department of Chemistry and Pharmacy, University of Sassari, Italy.
Cannabinoids, endogenous and exogenously administered, are known to positively regulate food intake and energy balance. Since CB1 receptor antagonists reduce food intake and antagonize overweight, we developed a new CB1 receptor antagonist in an attempt to identify a compound with potential application in overeating disorders. The newly developed SM-11 compound dose-dependently decreases food intake in rats by 15-20%. Moreover, SM-11 reduces self-administration of palatable food in both food restricted and ad libitum fed rats, suggesting an action on the hedonic component of food intake. Thus, we next tested the effect of SM-11 on the stimulating properties of the CB1 receptor agonist WIN55,212-2 (WIN) on the electrophysiological activity of Nucleus Accumbens-projecting dopaminergic neurons of the ventral tegmental area (VTA). SM-11 fully and readily antagonized the WIN-induced increments in single spiking and burst firing of antidromically-identified dopamine neurons. When administered to naïve (no WIN-pretreated) rats, SM-11 did not alter basal neuronal activity, thereby suggesting a pure antagonistic profile. SM-11 thus appears as a promising candidate in the search of potential anti-obesity medications.